Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B C Stevens

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
Leukemia & Lymphoma|October 14, 2025
Challenges in predicting outcomes for watch and wait follicular lymphoma patients: insights into clinical, pathological, and molecular factorsEva A M Hesius, James P Stewart, Leonie I Kroeze, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 7, 2020
Health-related quality of life after chemotherapy with or without rituximab in primary central nervous system lymphoma patients: results from a randomised phase III studyM van der Meulen, K Bakunina, M Nijland, et al.
Neuro-Oncology Advances|February 22, 2021
Extent of radiological response does not reflect survival in primary central nervous system lymphomaMatthijs van der Meulen, Alida A Postma, Marion Smits, et al.
Haematologica|December 21, 2014
Identification of IG-clonality status as a pre-treatment predictor for mortality in patients with immunodeficiency-associated Epstein-Barr virus-related lymphoproliferative disordersWalter J F M van der Velden, Loes Nissen, Marieke van Rijn, et al.
Histopathology|February 13, 2023
Reclassification of diffuse large B cell lymphoma to large B cell lymphoma with IRF4 rearrangement in an adult populationEva A M Hesius, Lidia van Laar, Margriet Oosterveld, et al.
The Lancet. Oncology|January 12, 2019
Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup studyJacoline E C Bromberg, Samar Issa, Katerina Bakunina, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 4, 2014
Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT)S Dietrich, A Boumendil, H Finel, et al.
Hemasphere|November 6, 2023
Clonal Relationship and Mutation Analysis in Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia Associated With Diffuse Large B-cell LymphomaMadeleine R Berendsen, Diede A G van Bladel, Eva Hesius, et al.
Journal of Hematology & Oncology|September 13, 2023
Genomic profiling of post-transplant lymphoproliferative disorders using cell-free DNANick Veltmaat, Yujie Zhong, Filipe Montes de Jesus, et al.
Neuro-Oncology|December 1, 2023
Survival, neurocognitive function, and health-related quality of life outcomes after rituximab-methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final results of the HOVON 105/ALLG NHL 24 studyJacoline E C Bromberg, Samar Issa, Bronno van der Holt, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Leukemia & Lymphoma|October 14, 2025
Challenges in predicting outcomes for watch and wait follicular lymphoma patients: insights into clinical, pathological, and molecular factorsEva A M Hesius, James P Stewart, Leonie I Kroeze, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 7, 2020
Health-related quality of life after chemotherapy with or without rituximab in primary central nervous system lymphoma patients: results from a randomised phase III studyM van der Meulen, K Bakunina, M Nijland, et al.
Neuro-Oncology Advances|February 22, 2021
Extent of radiological response does not reflect survival in primary central nervous system lymphomaMatthijs van der Meulen, Alida A Postma, Marion Smits, et al.
Haematologica|December 21, 2014
Identification of IG-clonality status as a pre-treatment predictor for mortality in patients with immunodeficiency-associated Epstein-Barr virus-related lymphoproliferative disordersWalter J F M van der Velden, Loes Nissen, Marieke van Rijn, et al.
Histopathology|February 13, 2023
Reclassification of diffuse large B cell lymphoma to large B cell lymphoma with IRF4 rearrangement in an adult populationEva A M Hesius, Lidia van Laar, Margriet Oosterveld, et al.
The Lancet. Oncology|January 12, 2019
Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup studyJacoline E C Bromberg, Samar Issa, Katerina Bakunina, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 4, 2014
Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT)S Dietrich, A Boumendil, H Finel, et al.
Hemasphere|November 6, 2023
Clonal Relationship and Mutation Analysis in Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia Associated With Diffuse Large B-cell LymphomaMadeleine R Berendsen, Diede A G van Bladel, Eva Hesius, et al.
Journal of Hematology & Oncology|September 13, 2023
Genomic profiling of post-transplant lymphoproliferative disorders using cell-free DNANick Veltmaat, Yujie Zhong, Filipe Montes de Jesus, et al.
Neuro-Oncology|December 1, 2023
Survival, neurocognitive function, and health-related quality of life outcomes after rituximab-methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final results of the HOVON 105/ALLG NHL 24 studyJacoline E C Bromberg, Samar Issa, Bronno van der Holt, et al.
Pageof 6